|
Leukemia, Myelocytic, Acute
|
0.300 |
Biomarker
|
disease |
CTD_human |
Discovery of epigenetically silenced genes in acute myeloid leukemias.
|
17330099 |
2007 |
|
Acute Myeloid Leukemia, M1
|
0.300 |
Biomarker
|
disease |
CTD_human |
Discovery of epigenetically silenced genes in acute myeloid leukemias.
|
17330099 |
2007 |
|
Dermatitis, Allergic Contact
|
0.300 |
Biomarker
|
disease |
CTD_human |
Gene expression time course in the human skin during elicitation of allergic contact dermatitis.
|
17597826 |
2007 |
|
Acute Myeloid Leukemia (AML-M2)
|
0.300 |
Biomarker
|
disease |
CTD_human |
Discovery of epigenetically silenced genes in acute myeloid leukemias.
|
17330099 |
2007 |
|
Multiple Sclerosis
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis.
|
24076602 |
2013 |
|
melanoma
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
GILT protein expression in melanocytes was induced in halo nevi, which are nevi undergoing immune-mediated regression, and is consistent with the association of GILT expression with improved survival in melanoma.
|
31591149 |
2019 |
|
melanoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
GILT staining in antigen-presenting cells (APCs) was detected in 100% of primary and metastatic melanomas versus 31% of nevi, and it was typically intense.
|
26930048 |
2016 |
|
melanoma
|
0.050 |
Biomarker
|
disease |
LHGDN |
These data suggest that GILT-expressing melanoma cells could prove to be very promising for direct antigen presentation and CD4+ T cell recognition, and may have direct implications for the design of cancer vaccines.
|
18343923 |
2008 |
|
melanoma
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
In contrast with professional APCs such as B cells, class II-positive human melanomas expressed relatively little to no GILT protein or mRNA.
|
15240658 |
2004 |
|
melanoma
|
0.050 |
Biomarker
|
disease |
LHGDN |
The absence of GILT in melanomas altered antigen processing and the hierarchy of immunodominant epitope presentation.
|
12021307 |
2002 |
|
Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
Also, the knockdown of GILT inhibits tumor growth in vivo.
|
30587343 |
2019 |
|
Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
The role of gamma-interferon-inducible lysosomal thiol reductase (GILT) in tumor immunosurveillance has recently been studied in several malignant diseases, but its role in breast cancer remains to be elucidated.
|
25333930 |
2014 |
|
Glioma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
GILT was highly expressed as observed in the public database on human gliomas and two human glioma cell lines, U373MG and U87MG cells.
|
30587343 |
2019 |
|
Lassa Fever
|
0.010 |
Biomarker
|
disease |
BEFREE |
While overexpression of GILT inhibited the entry mediated by envelope glycoproteins of SARS coronavirus (SARS-CoV), Ebola virus (EBOV) and Lassa fever virus (LASV), depletion of GILT enhanced the entry mediated by these viral envelope glycoproteins.
|
31631785 |
2019 |
|
Hemorrhagic Fever, Ebola
|
0.010 |
Biomarker
|
disease |
BEFREE |
While overexpression of GILT inhibited the entry mediated by envelope glycoproteins of SARS coronavirus (SARS-CoV), Ebola virus (EBOV) and Lassa fever virus (LASV), depletion of GILT enhanced the entry mediated by these viral envelope glycoproteins.
|
31631785 |
2019 |
|
Halo nevus
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
GILT protein expression in melanocytes was induced in halo nevi, which are nevi undergoing immune-mediated regression, and is consistent with the association of GILT expression with improved survival in melanoma.
|
31591149 |
2019 |
|
Carcinogenesis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
However, the role of GILT in the tumorigenesis of glioma remains unknown.
|
30587343 |
2019 |
|
Autoimmune Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
Through manipulation of the balance between oxidative and reductive capacities in the phagosome-principally by modulating NADPH oxidase (NOX2) and γ-interferon-inducible lysosomal thiol reductase (GILT) activities-studies have demonstrated changes to antigen processing patterns leading to modified repertoires of antigenic peptides available for presentation, and subsequently, altered disease progression in T cell-driven autoimmunity.
|
29578071 |
2018 |
|
Metastatic melanoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Here we report that GILT expression inhibits a potential target, paired box-3 (PAX-3) protein, in late stage human metastatic melanoma.
|
28857256 |
2018 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
FTO (OR = 1.71; CI<sub>95 %</sub> = 1.14-2.57; p = 0.008) and APOB (OR = 0.31; CI<sub>95 %</sub> = 0.14-0.72; p = 0.004) result is statistically associated to high blood pressure and FTO (OR = 2.0; CI<sub>95 %</sub> = 1.3-3.1; p = 0.001), GNB3 (OR = 2.69; CI<sub>95 %</sub> = 1.0-7.2; p = 0.04), IFI30 (OR = 2.0; CI<sub>95 %</sub> = 1.16-3.6; p = 0.01), and MC4R (OR = 1.81; CI<sub>95 %</sub> = 1.13-2.9; p = 0.01) to type 2 diabetes (T2D).
|
28035522 |
2017 |
|
Nevi and Melanomas
|
0.010 |
AlteredExpression
|
group |
BEFREE |
We evaluated GILT and MHC class II expression in human primary and metastatic melanomas and nevi using immunohistochemical analysis.
|
26930048 |
2016 |
|
Malignant neoplasm of breast
|
0.010 |
Biomarker
|
disease |
BEFREE |
In addition, absence of GILT was positively correlated with adverse characteristics of breast cancers, such as histological type, tumor size, lymph nodes status, and pTNM stage (P<0.05).
|
25333930 |
2014 |
|
Breast Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
To further determine the role of GILT in breast cancer, we examined GILT expression in breast cancers as well as noncancerous breast tissues by immunohistochemistry and real-time PCR, and assessed its association with clinicopathologic characteristics and patient outcome.
|
25333930 |
2014 |
|
Tumor Immunity
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
These findings indicate that GILT may act as a tumor suppressor in breast cancer, in line with its previously suggested role in anti-tumor immunity.
|
25333930 |
2014 |
|
Hemophilia B
|
0.010 |
Biomarker
|
disease |
BEFREE |
The results show that administering 500 μL of NMP via IV or IP 30 min in advance enables surgical procedures to be safely performed on HB mice, and that IV administration is more desirable than IP if the procedure requires opening of the abdominal wall.
|
23855819 |
2013 |